Advanced Medical Optics, Inc. (AMO) (NYSE:EYE), a global leader in ophthalmic surgical devices and eye care products, today announced that it has entered into a U.S. patent license agreement with Carl Zeiss Meditec AG, a global leader in ophthalmic and surgical devices and instrumentation. Within the scope of this agreement, AMO's IntraLase subsidiary has granted a non-exclusive, royalty-bearing license to Carl Zeiss Meditec to use the IntraLase patent portfolio to provide femtosecond technology for corneal surgery. Other terms of the agreement are confidential.
About Advanced Medical Optics (AMO)
AMO develops advanced, life-improving vision technologies for people of all ages. Products in the cataract/implant line include intraocular lenses (IOLs), phacoemulsification systems, viscoelastics, and related products used in ocular surgery. AMO owns or has the rights to such product brands as ReZoom®, Tecnis®, Clariflex®, Sensar®, and Verisyse® IOLs, Sovereign®, Sovereign® Compact and WhiteStar Signature phacoemulsification systems with WhiteStar® technology, Healon® viscoelastics, and the Baerveldt®glaucoma shunt. Products in the laser vision correction line include wavefront diagnostic devices, femtosecond lasers and associated patient interface devices, and excimer laser vision correction systems and treatment cards. AMO brands in the laser vision correction business include Star S4 IR®, WaveScan Wavefront®, Advanced CustomVue, IntraLase® and IntraLasik®. Products in the contact lens care line include disinfecting solutions, enzymatic cleaners and lens rewetting drops. Among the eye care product brands the company possesses are COMPLETE®, COMPLETE® Blink-N-Clean®, Consept®F, Consept® 1 Step, Oxysept® 1 Step, UltraCare®, Ultrazyme®, Total Care and blinkbranded products. AMO is based in Santa Ana, California, and employs approximately 4,200 worldwide. The company has operations in 24 countries and markets products in approximately 60 countries. For more information, visit the company's Website at www.amo-inc.com.